↓ Skip to main content

Tumor homologous recombination deficiency assays: another step closer to clinical application?

Overview of attention for article published in Breast Cancer Research, July 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tumor homologous recombination deficiency assays: another step closer to clinical application?
Published in
Breast Cancer Research, July 2014
DOI 10.1186/s13058-014-0409-7
Pubmed ID
Authors

Shane R Stecklein, Priyanka Sharma

Abstract

Inherited and acquired defects in homologous recombination, a phenotype termed 'BRCAness', may lend to therapeutic exploitation in breast cancer. To this end, development and clinical evaluation of platforms to identify signatures of BRCAness are of immense interest. In this issue of Breast Cancer Research, Vollebergh and colleagues report that a BRCA-like array comparative genomic hybridization (aCGH) genomic instability signature is associated with benefit from high-dose cyclophosphamide-thiotepa-carboplatin chemotherapy. We discuss the strengths and weaknesses of this study and consider the clinical significance and applicability of this aCGH BRCAness signature in the context of other existing homologous recombination deficiency detection platforms.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 5%
Germany 1 5%
Unknown 20 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 32%
Student > Master 3 14%
Student > Bachelor 2 9%
Student > Ph. D. Student 2 9%
Student > Postgraduate 2 9%
Other 4 18%
Unknown 2 9%
Readers by discipline Count As %
Agricultural and Biological Sciences 8 36%
Medicine and Dentistry 6 27%
Biochemistry, Genetics and Molecular Biology 3 14%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Chemical Engineering 1 5%
Other 0 0%
Unknown 3 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2014.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Breast Cancer Research
#1,883
of 2,053 outputs
Outputs of similar age
#206,120
of 240,094 outputs
Outputs of similar age from Breast Cancer Research
#26
of 33 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,094 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.